Raymond James Financial Services Advisors, Inc. Dyne Therapeutics, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 38,782 shares of DYN stock, worth $917,194. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,782
Previous 38,788
0.02%
Holding current value
$917,194
Previous $1.37 Million
1.83%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DYN
# of Institutions
209Shares Held
102MCall Options Held
234KPut Options Held
238K-
Atlas Venture Life Science Advisors, LLC8.02MShares$190 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$175 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$162 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$161 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$161 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.22B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...